CBIZ Investment Advisory Services LLC Buys Shares of 400 Repligen Co. (NASDAQ:RGEN)

CBIZ Investment Advisory Services LLC bought a new position in Repligen Co. (NASDAQ:RGEN) during the fourth quarter, HoldingsChannel.com reports. The fund bought 400 shares of the biotechnology company’s stock, valued at approximately $58,000.

Several other institutional investors also recently bought and sold shares of RGEN. Resources Management Corp CT ADV purchased a new position in Repligen in the 3rd quarter worth approximately $37,000. Quarry LP grew its stake in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 239 shares during the period. UMB Bank n.a. grew its stake in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 110 shares during the period. Global Retirement Partners LLC raised its stake in Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 129 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 90 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RGEN shares. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. Royal Bank of Canada lifted their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. Canaccord Genuity Group boosted their price objective on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Finally, JPMorgan Chase & Co. upped their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Stock Performance

Repligen stock opened at $150.62 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market capitalization of $8.44 billion, a P/E ratio of -295.33, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $200.23. The company’s 50-day moving average is $157.19 and its 200 day moving average is $148.50.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Research analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.